Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information.

Highlights in Medicinal Chemistry II

23 November 2016 09:00-17:00, London, United Kingdom


Introduction

Synopsis

This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.

Attendees

This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.

Programme

09.00 Registration and refreshments

09.50 Opening remarks

09.55 The realisation of activity-directed synthesis Prof Adam Nelson, University of Leeds

10.35 Structure-based design of drug-like macrocycles to probe the role of MTH1 in cancer
Dr Jason Kettle, AstraZeneca

11.15 Refreshments

11.35 Development of novel, selective and irreversible PI3K inhibitors
Mr Samuel Dalton, University of Strathclyde / GlaxoSmithKline

12.00 Discovery of the first cell-active inhibitors of poly(ADP ribose) glycohydrolase (PARG) through high-throughput screening and computational approaches
Dr Kate Smith, Cancer Research UK Manchester Institute

12.25 Discovery of a small molecule that mitigates hearing loss in a model of Usher syndrome III
Dr Chris Lock, Discovery from Charles River

12.50 Lunch

13.50 Discovery of novel TACE inhibitors for topical treatment of psoriasis
Dr Gilles Ouvry, Galderma

14.15 Discovery of CCT251921: A potent, selective and orally bioavailable small molecule modulator of the mediator complex-associated kinases CDK8 and CDK19
Dr Aurélie Mallinger, The Institute of Cancer Research

14.40 Increasing solubility for free
Dr Timothy Ritchie, TJR-Chem

15.20 Refreshments

15.40 Extracting actionable knowledge from large scale in vitro pharmacology data
Dr Al Dossetter, MedChemica

16.05 Receptor kinetics vs CNS exposure: which is more important for a ghrelin inverse agonist?
Dr William McCoull, AstraZeneca

16.30 Chemical probes for epigenetic proteins
Prof Paul Brennan, University of Oxford

17.10 Closing remarks

17.15 Wine reception

Sponsorship

If you are interested in in sponsorship opportunities, please contact conferences@soci.org.
Venue
SCI

SCI, SCI, 14/15 Belgrave, Select, London, SW1X 8PS, United Kingdom

Committee
  • Joanne Pinder Vertex Pharmaceuticals Eur Ltd, United Kingdom
  • Sarah Major Evotec (UK) Ltd, United Kingdom
  • Iain Simpson AstraZeneca, United Kingdom
  • Mihiro Sunose Sygnature Discovery Ltd, United Kingdom
  • Nigel Swain Pfizer, United Kingdom

Organised by
Organised by SCI’s Fine Chemicals Group
Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*